<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345471</url>
  </required_header>
  <id_info>
    <org_study_id>MD120101</org_study_id>
    <secondary_id>JapicCTI-205252</secondary_id>
    <nct_id>NCT04345471</nct_id>
  </id_info>
  <brief_title>A Study of MD-120 in Patients With Depression</brief_title>
  <official_title>A Placebo-controlled Study of MD-120 in Patients With Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mochida Pharmaceutical Company, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to verify the efficacy and evaluate the safety of 8-week
      once-daily oral administration of MD-120 in Japanese patients with depression.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Montgomery-Asberg Depression Rating Scale (MADRS) Total Score: Scale ranges from 0 to 60 with a higher score indicating worsening symptoms of depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hamilton Depression Rating Scale-17 (HAM-D17) Total Score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Hamilton Depression Rating Scale-17 (HAM-D17) Total Score: Scale ranges from 0 to 52 with a higher score indicating worsening symptoms of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reactions (ADRs)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of desvenlafaxine</measure>
    <time_frame>Week 2 through week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">594</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>MD-120 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MD-120 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine 100 mg</intervention_name>
    <description>once daily dosing for 8 weeks</description>
    <arm_group_label>MD-120 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine 50 mg</intervention_name>
    <description>once daily dosing for 8 weeks</description>
    <arm_group_label>MD-120 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily dosing for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with diagnosis of Major Depressive Disorder (MDD) based on the criteria in the
             Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5).

          -  HAM-D 17 total score of â‰¥20.

        Exclusion Criteria:

          -  Patient who meets DSM-5 criteria of the following disorders for current or past
             history.

        Schizophrenia spectrum and other psychotic disorders Bipolar and related disorders
        Substance use disorders (exclusive of tobacco and caffeine)

          -  Patient who had suicidal behavior in Columbia-Suicide Severity Rating Scale (C-SSRS)
             within 1 year before start of screening phase.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koichi Hayashi</last_name>
    <role>Study Director</role>
    <affiliation>Mochida Pharmaceutical Company, Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mochida Clinical Research Department</last_name>
    <phone>+81-3-3225-6332</phone>
    <email>clinical.trials.contact@mochida.co.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mochida Public Relations Office</last_name>
    <email>webmaster@mochida.co.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mochida Investigational sites</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 6, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

